Solvonis Therapeutics PLC
SVNS
Company Profile
Business description
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Contact
Eccleston Yards
25 Eccleston Place
LondonSW1W 9NF
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
We believe Disney’s irreplaceable characters will continue to drive a healthy experiences business, which we estimate is worth nearly as much as the market values the whole firm.
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,721.93 | 22.22 | 0.26% |
| DAX 40 | 26,322.53 | 182.40 | 0.70% |
| Dow JONES (US) | 53,959.32 | 74.22 | 0.14% |
| FTSE 100 | 10,916.78 | 48.89 | 0.45% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,529.02 | 180.66 | 0.69% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,729.19 | 19.23 | 0.25% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |